Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences
Login
Login
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart and MadeAi, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

98 articles published Follow:
Revolutionizing Protocol

Revolutionizing Protocol Generation: How Agentic AI Drafts Compliant Plans in Minutes

BlogAugust 4, 202668Views0Likes0Comments
Consider a cross-functional team huddled around spreadsheets, regulatory guidelines, and past trial data, spending weeks or sometimes months crafting a single clinical trial protocol; see protocol structure details. Every inclusion criterion, endpoint, and safety measure must align perfectly with ICH-GCP standards, FDA expectations, and real-world feasibility. One misalignment, and you risk costly amendments, delayed starts,…

Read More

Deploying AI in Drug Discovery

Deploying AI in Drug Discovery: Moving Past the Hype

White PaperJuly 28, 202676Views0Likes0Comments
Drug discovery is evolving rapidly, but successful AI adoption requires more than powerful models. It demands validated evidence, robust governance, and realistic expectations. AI empowers life sciences teams to accelerate drug discovery through evidence synthesis and expert human validation, delivering faster scientific insights while maintaining transparency, traceability, and regulatory-grade quality. Download Deploying AI in Drug…

Read More

AI for Patient-Reported Outcomes

How AI is Scaling Patient-Reported Outcomes into Structured, Submission-Ready Evidence

BlogJuly 28, 202653Views0Likes0Comments
Scaling Patient-Reported Outcomes In the world of clinical research and drug development, patients’ own voices matter more than ever. Patient-reported outcomes (PROs) capture how people actually feel, their symptoms, quality of life, side effects, and daily functioning. Yet turning these often messy, free-text or survey responses into clean, structured data that regulators can trust has…

Read More

Ready Evidence Dossiers

How AI Helps HEOR Teams Build HTA-Ready Evidence Dossiers

BlogJuly 23, 202667Views0Likes0Comments
HTA-Ready Evidence Dossiers HTA (Health Technology Assessment)-ready evidence dossiers represent a critical deliverable for HEOR teams seeking market access and reimbursement for new therapies. These documents compile clinical, economic, and real-world evidence to meet strict requirements from health technology assessment bodies such as NICE, CADTH, or HAS. HTA-ready evidence dossiers demand more data, tighter timelines,…

Read More